Haematopoetic stem/progenitor cell therapy - Nohla Therapeutics

Drug Profile

Haematopoetic stem/progenitor cell therapy - Nohla Therapeutics

Alternative Names: Ex vivo expanded universal donor cellular therapies - Nohla Therapeutics; Ex vivo-expanded cord blood progenitor cells - Nohla Therapeutics; Haematopoetic progenitor cell therapy - Nohla Therapeutics; NLA 101; Notch-mediated ex vivo expanded cord blood HSPC - Nohla Therapeutics

Latest Information Update: 18 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Fred Hutchinson Cancer Research Center
  • Developer Fred Hutchinson Cancer Research Center; Nohla Therapeutics
  • Class Antibacterials; Antineoplastics; Radioprotectives; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Haematological malignancies
  • Preclinical Acute radiation syndrome; Graft-versus-host disease; Neutropenia; Sepsis

Most Recent Events

  • 04 Oct 2017 Nohla Therapeutics plans the phase II LAUNCH trial for Acute myeloid leukaemia (NCT03301597)
  • 28 Mar 2017 Nohla Therapeutics signs a manufacturing and supply agreement with University of California, Davis for development and commercialisation of haematopoetic stem/progenitor cell therapy
  • 10 Jan 2017 Preclinical trials in Graft-versus-host disease (Prevention) in USA (unspecified route) (Nohla Therapeutics pipeline, January 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top